Date Title Description PDF
26 Jul 2023 On buy-back programmes The Company reports the commencement, effective as of today, 26 July 2023, of a share buyback program.   Download
10 May 2023 On P&L The Company releases the first quarter 2023 financial results presentation Download
10 May 2023 On P&L The Company releases the press release related to the first quarter 2023 financial results Download
25 Apr 2023 On business and financial situation ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) Download
21 Feb 2023 On business and financial situation The Company releases the press release related to the full year 2022 financial results. Download

Pages

Date Title Description PDF
10 Apr 2023 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the first quarter of 2023 Download
21 Feb 2023 Annual Corporate Governance Report ROVI releases the 2022 Annual Corporate Governance Report Download
21 Feb 2023 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2022 annual report regarding remuneration of the members of the Board of Directors Download
16 Feb 2023 On business and financial situation The Company informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone ISM®) in the United States. Download
09 Jan 2023 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the fourth quarter of 2022 Download

Pages

Date Title Description PDF
07 Nov 2011 Otros sobre Gobierno Corporativo Download
19 Oct 2011 I+D resultados obtenidos; licencias, patentes y marcas Download
26 Sep 2011 Acuerdos estratégicos con terceros Download
23 Sep 2011 Acuerdos estratégicos con terceros Download

Pages